New Society Aims to Advance China’s Gene and Cell Therapy Sector

BEIJING, Sept. 14, 2025 — In a significant development for China’s burgeoning cell and gene therapy (CGT) sector, the Chinese Society of Gene and Cell Therapy was officially launched and held its inaugural annual meeting in Beijing. The society, co-founded by Mark Kay, a prominent figure in the American Society of Gene and Cell Therapy, aims to address key challenges and bolster China’s position in the global CGT landscape.

The society’s core focus will be on advancing policy support, academic research, clinical trials, and international collaboration. According to industrial observers, the organization’s establishment is a major step toward integrating China’s CGT products into the global market and will help create a platform for international resource sharing.

The annual meeting, co-hosted by the administrative commission of Zhongguancun Science City, attracted nearly 2,000 participants, including leading scientists, clinicians, entrepreneurs, and investors. Officials from the Beijing Municipal Science and Technology Commission highlighted Beijing’s leadership in the medical and health industry, noting that the sector reached a scale of 1.06 trillion yuan in 2024. Beijing’s Haidian district, home to top institutions like Tsinghua and Peking universities, has become a hub for innovation in the field.

During the meeting, a comprehensive “blue book” on the development and regulatory policies of China’s CGT industry was released. The document is expected to provide a framework for dialogue between industry leaders and regulators, further streamlining the pathway for new therapies.